Back to results
US 10,441,595 B2Granted
Methods for treating fungal infections
AssigneeBrigham Young University
InventorsCarl Genberg, Chad S. Beus, Paul B. Savage
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
Claims41
A method of treating a fungal infection, comprising:
- identifying a patient in need of treatment for a fungal infection caused by one or more fungi selected from the group consisting of Trichophyton rubrum, Trichophyton mentagrophytes, terbinafine-resistant Trichophyton rubrum, Candida albicans, fluconazole-resistant Candida albicans, Candida krusei, fluconazole-resistant Candida krusei, fluconazole-resistant Candida glabrata, Candida parapsilosis, Trichophyton tonsurans, Microsporum canis, Aspergillus fumigatus, Aspergillus niger, Penicillium sp., and Cladosporium sp.,
- administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA) of Formula III, or a pharmaceutically acceptable salt thereof, to the patient in need thereof in order for the CSA to provide antifungal activity against the one or more fungi:
- where,
- R3, R7, and R12 are unsubstituted aminoalkyloxy;
- and
- R18 is unsubstituted alkylaminoalkyl, and
- the therapeutically effective amount of the at least one CSA, or a pharmaceutically acceptable salt thereof, treating the fungal infection by providing antifungal activity in the patient against the one or more fungi.
4 more elements
A method of treating a patient having fungal infection associated with Candida albicans or fluconazole-resistant Candida albicans, comprising:
- identifying a patient in need of treatment for a fungal infection caused by Candida albicans or fluconazole-resistant C. albicans,
- administering to the patient a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA) comprising CSA-131, or a pharmaceutically acceptable salt thereof, and
- the therapeutically effective amount of the at least one CSA comprising CSA-131, or a pharmaceutically acceptable salt thereof, treating the fungal infection by providing antifungal activity in the patient against the Candida albicans or fluconazole-resistant C. albicans.
A method of treating a fungal infection, comprising:
- identifying a patient in need of treatment for a fungal infection caused by one or more fungi selected from the group consisting of Trichophyton rubrum, Trichophyton mentagrophytes, terbinafine-resistant Trichophyton rubrum, Candida albicans, fluconazole-resistant Candida albicans, Candida krusei, fluconazole-resistant Candida krusei, fluconazole-resistant Candida glabrata, Candida parapsilosis, Trichophyton tonsurans, Microsporum canis, Aspergillus fumigatus, Aspergillus niger, Penicillium sp., and Cladosporium sp.,
- administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof, to the patient in need thereof in order for the CSA to provide antifungal activity, and
- the therapeutically effective amount of the at least one CSA, or a pharmaceutically acceptable salt thereof, treating the fungal infection by providing antifungal activity in the patient against the one or more fungi,
- wherein the CSA, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
- and pharmaceutically acceptable salts of the foregoing.
2 more elements
A method of treating a fungal infection, comprising:
- identifying a patient in need of treatment for a fungal infection caused at least in part by one or more of fluconazole-resistant Candida albicans, fluconazole-resistant Candida krusei, fluconazole-resistant Candida glabrata, or terbinafine-resistant Trichophyton rubrum,
- selecting a cationic steroid antimicrobial (CSA) of Formula III, or a pharmaceutically acceptable salt thereof, to be administered to the patient:
- where,
- R3, R7, and R12 are unsubstituted aminoalkyloxy;
- and
- R18 is unsubstituted alkylaminoalkyl,
- wherein the CSA is selected by measuring a biomarker or subjecting a sample from the patient to a companion diagnostic device in the patient;
- administering a therapeutically effective amount of the selected CSA to the patient in need thereof in order for the selected CSA to provide antifungal activity against one or more fungi causing the fungal infection;
- and
- the therapeutically effective amount of the selected CSA treating the fungal infection by providing antifungal activity in the patient against one or more fungi causing the fungal infection.
7 more elements
Dependencies are inferred from the claim text.